TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01713400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: One subcutaneous injection administered on day -1 and repeated on day +20 after transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus
Description: Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
Study: NCT01828099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was administered by iv infusion at a dose of 75 mg/m\^2 every 21 days for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
Study: NCT02117830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 250 Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400 mg
Study: NCT03999008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide Oral
Description: The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance.
Study: NCT02518932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Last 5 amino acids of GLP-1
Description: To examine insulinomimetic properties of LVKGR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline
Study: NCT04613089

Intervention type: OTHER
Intervention: Natural History
Description: Natural History and Clinical Follow Up.
Study: NCT00129675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]ß CIT
Description: Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Study: NCT01713400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
Study: NCT02226510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XL
Description: In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
Study: NCT01143597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm and hand training
Description: Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm and hand training
Description: Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm and hand training
Description: Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
Study: NCT02005601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg
Description: Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
Study: NCT04613089

Intervention type: OTHER
Intervention: Natural History
Description: Natural History and Clinical Follow Up.

Intervention type: OTHER
Intervention: Natural History
Description: Natural History and Clinical Follow Up.

Intervention type: OTHER
Intervention: Natural History
Description: Natural History and Clinical Follow Up.

Intervention type: OTHER
Intervention: Natural History
Description: Natural History and Clinical Follow Up.
Study: NCT00724035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus
Study: NCT00724035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.75% (wt/vol) solution, 20 ml perineural injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.75% (wt/vol) solution, 20 ml perineural injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50 µg iv bolus prn for pain during surgery, up to 150 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 50 µg iv bolus prn for pain during surgery, up to 150 µg
Study: NCT02789332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PwO
Description: paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PwCb
Description: paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC
Description: both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC
Description: both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery after neoadjuvant Therapy
Description: In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery after neoadjuvant Therapy
Description: In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stratification
Description: Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratification
Description: Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years
Study: NCT01195077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seaweed, spirulina, seaweed + spirulina
Description: Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Study: NCT00318227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: Blood transfusion will be administered when the transfusion trigger is met.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: Blood transfusion will be administered when the transfusion trigger is met.
Study: NCT00235495

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: equivalent volume of isotonic saline control
Study: NCT04613089

Intervention type: OTHER
Intervention: Natural History
Description: Natural History and Clinical Follow Up.

Intervention type: OTHER
Intervention: Natural History
Description: Natural History and Clinical Follow Up.
Study: NCT04061473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: 2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: 2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
Study: NCT01920776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound examination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Description: Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
Study: NCT02351895

Intervention type: OTHER
Intervention: Copper impregnated linen
Description: Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
Study: NCT04061473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: 2 tablets of empagliflozin 25 mg.
Study: NCT06077825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative rehabilitation
Description: 30 patients took postoperative rehabilitation after total hip arthroplasty surgery, 3 times a week, for 6 weeks. They took conventional rehabilitation (hip range of motion exercises, progressive strengthening exercises for hip and knee muscles, balance and proprioceptive exercises and gait training).
Study: NCT02589925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vercise deep brain stimulation
Description: implantation of a Vercise neurostimulation system
Study: NCT01829763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection botox
Study: NCT02589925

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vercise deep brain stimulation
Description: implantation of a Vercise neurostimulation system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subthalamic nucleus (STN) stimulation
Description: bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: subthalamic nucleus (STN) stimulation
Description: bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NBM stimulation
Description: bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
Study: NCT01084759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone injection
Description: Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
Study: NCT03999008

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Apple Sauce 5 mL+ 1 mL saline
Study: NCT05172687

Intervention type: BEHAVIORAL
Intervention: Overprescribing letter to attributed physician
Description: Letter telling patient's attributed physician they were under review for high prescribing
Study: NCT04279769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-280
Description: CB-280, oral capsule administered twice daily at the assigned dose level for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-280
Description: CB-280, oral capsule administered twice daily at the assigned dose level for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-280
Description: CB-280, oral capsule administered twice daily at the assigned dose level for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-280
Description: CB-280, oral capsule administered twice daily at the assigned dose level for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
Study: NCT05172687

Intervention type: BEHAVIORAL
Intervention: Overprescribing letter to attributed physician
Description: Letter telling patient's attributed physician they were under review for high prescribing

Intervention type: BEHAVIORAL
Intervention: Placebo letter to attributed physician
Description: Letter to patient's attributed physician about unrelated Medicare regulation
Study: NCT02589925

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
Study: NCT04751864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electrotherapy Stimulator (CES) Device
Description: Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cranial Electrotherapy Stimulator (CES) Device
Description: Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device
Study: NCT00707369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Metronidazole
Description: tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
Study: NCT05172687

Intervention type: BEHAVIORAL
Intervention: Placebo letter to attributed physician
Description: Letter to patient's attributed physician about unrelated Medicare regulation
Study: NCT03515473

Intervention type: DEVICE
Intervention: cochlear implant
Description: cochlear implant surgery

Intervention type: DEVICE
Intervention: cochlear implant
Description: cochlear implant surgery

Intervention type: DEVICE
Intervention: cochlear implant
Description: cochlear implant surgery
Study: NCT01044823

Intervention type: OTHER
Intervention: 3D and thermal imaging
Description: subjects will be imaged before and after receiving DMARD therapy

Intervention type: OTHER
Intervention: 3D and thermal imaging
Description: subjects will be imaged before and after receiving DMARD therapy
Study: NCT04533620

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standardized CIRT
Description: CIRT with a dose of 63 GyE/21 fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Individualized CIRT
Description: A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
Study: NCT00901719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apelin
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium nitroprusside
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic apelin infusion
Description: Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic apelin infusion
Description: Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
Study: NCT01283763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Imiquimod
Description: 16 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conization
Description: Large loop excision of the transformation zone
Study: NCT03406845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chair-side mindfulness intervention
Description: Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chair-side mindfulness intervention
Description: Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP).
Study: NCT04766905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini Lateral Shoulder Approach (MLSA)
Description: The skin incision is about 4 to 5 cm made by the distal acromial edge in sagittal plane, The dissection takes place slightly over the acromial edge proximally and over the origin of the acromial deltoid part (the middle part of deltoid origin) distally.~After clearly revealing the region of the medial deltoid origin on the acromion, the acromionic deltoid origin is skinned only; of the edge of the acromion, and that maybe accrued by electric knife pen or periosteal elevator, without exposure the clavicular deltoid origin in the front and the deltoid origin on the spine of scapula in the back, the origin of the acromial deltoid is distanced laterally and distally, where the lateral edge, the lower surface of the acromion, under acromial bursa and the rotator cuff are exposed clearly.